SUNU Ventures

Investment decisions are led by Managing Partners Craig Boyce and Felix von Coerper, with scientific review from Chief Scientific Officer Dr. Melanie Leitner and due diligence support from Dr. Olivier Tak. An investment committee advisor, Rist Brouwer, provides additional oversight, per the firm’s website.

The firm does not detail its sourcing channels publicly, but its structure — with an in-house CSO and an MD dedicated to science and due diligence — suggests deal flow originates through clinical and research networks rather than broker-led processes. No external sourcing partnerships or co-investor clubs are disclosed.

It operates as a specialized Venture Capital fund, not a family office. Its public-facing entity, ALS Investment Fund, pools external capital to invest in early-stage biotech companies. No single-family wealth source or family-office structure is disclosed.

The firm has not published its fund-structure preferences, but its positioning as a VC fund directly backing drug-development companies indicates a primary focus on direct early-stage investments. No fund-of-funds activity or LP commitments to outside managers are reported.

SUNU Ventures targets early stage, specifically start-up and venture-stage companies, according to its own materials. The firm concentrates on the preclinical and clinical development phases for ALS and related neurodegenerative therapies.

No philanthropic foundation or donor-advised fund is listed alongside the firm. Its operating structure, as presented publicly, consists solely of the ALS Investment Fund vehicle; any charitable work is not disclosed on its website.

The firm has not publicly stated a co-investment policy. Its sparse public record does not name any co-investors, syndicate partners, or external GPs participating in its deals.